Effectiveness of BNT162b2 in children aged 5-11 peaks at 38.7% at 0-14 days and drops to 21.2% at 43-84 days.
They even have a nice graph and everything.
At a 0.002% childhood IFR (lower because that was pre-Omicron), 38.7% or 21.2% effectiveness brings childhood IFR down to 0.0013% or 0.0016%, a big achievement.
Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5–11 years in Italy: a retrospective analysis of January–April, 2022
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01185-0/fulltext
Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications.
https://pubmed.ncbi.nlm.nih.gov/33289900/
Someone ought to compare this to the childhood adverse reaction rate.